**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Eli Muchtary, Mayo Clinic, Rochetster, MN, USA

**Main Body of the Abstract**
Stem cell transplant-related mortality (TRM) decreased owing to improvements in patient selection. New therapeutic options challenge the utilization of autologous stem cell transplantation (ASCT) in AL amyloidosis. Combining functional and organ impairment measures into a predictive scoring model can improve patient selection and reduce TRM.
AL amyloidosis patients (n=1718) transplanted between 2003-2020 from 9 centers were included. Pre-ASCT organ function data were obtained. A random forest (RF) classifier with 10-fold cross-validation was used for variable selection. The final model was fitted using logistic regression.
The median age was 59. The most involved organs were kidney (69%) and heart (52%). Mayo 2004 stage I-II was present in 83% of patients. 54% of patients received Induction. Seventy-five patients (4.4%) died within 100 days of transplant. Ten factors were predictive for day-100 TRM on univariate analysis with an odds ratio (OR) of 1.99-3.93 (Table). RF classifier using all these variables created a model with an area under the curve (AUC) of 0.69±0.13. Using SHAP function to refine the model selection, a 6-variable model was built with an AUC of 0.7±0.13. The following variables are included in the final model: NT-proBNP/BNP, serum albumin, ECOG score, dFLC, cDLCO, and systolic blood pressure. With 1 point for each variable, the 3-month TRM was 1.5%, 3.7%, 4.9%, and 18.4% for 0, 1, 2, >2 points, respectively.
We created a model to predict TRM in AL amyloidosis undergoing ASCT. The included domains reflect the heterogeneity of this disease and the various causes of TRM among patients.



A predictive model for day-100 transplant-related mortality in AL amyloidosis  PA129 (#456)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.